News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.

It will be the first AMN clinical study to utilize wearable technology for monitoring patient activity and outcomes.

Benjamin Harrison, BSc, PhD, assistant professor of biochemistry and nutrition at UNE, shared his thoughts on the research.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the panel discussion she participated in at BIO 2022.

Michael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.

The hold was related to a serious adverse event of hypomagnesemia in an ongoing phase 2 clinical trial.

The hold comes after a serious AE of peripheral sensory neuropathy.

The senior vice president of clinical development at Passage Bio discussed intracisternal magna administration of PBGM01.

The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.

Review top news and interview highlights from the week ending June 24, 2022.

BioMarin received a positive CHMP opinion after the FDA delayed val-rox's BLA filing for the second time.

B-VEC recently showed efficacy in the phase 3 GEM-3 trial.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

NfL peaked 1-month post-treatment as expected and returned to near baseline at 12 months.

The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Long term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.

Annualized bleeding rate fell to 0 at a median of 58 weeks after infusion.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.

All children in the phase 3 SPR1NT study achieved the primary end point of independent sitting.

Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.

The chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.

ACE1831 will soon be evaluated in a phase 1, first-in-human, clinical trial.

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.